Key facts
- This page summarizes Robert Dee Etherington's Form 4 filing for Clene Inc. (CLNN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 19 Jul 2022, 16:08.
Robert Dee Etherington - 18 Jul 2022 Form 4 Insider Report for Clene Inc. (CLNN)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CLNN
- Reported as of
- 18 Jul 2022
- Net transaction value
- -$110,840
- SEC form
- 4
- Accepted by SEC
- 19 Jul 2022, 16:08:31 UTC
- Prior SEC filing
- 16 Feb 2022
- Next SEC filing
- 07 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jerry Miraglia POA
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Dee Etherington filed Form 4 for Clene Inc. (CLNN) on 19 Jul 2022.
Change
- Previous filing in this sequence was filed on 16 Feb 2022.
- Current net transaction value: -$110,840.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLNN
transaction
Common Stock
Sale
- Transaction value
- $110,840
- Shares
- -23,483
- Change %
- -29%
- Price
- $4.72*
- Shares after
- 56,593
- Date
- 18 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
CLNN
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,717
- Date
- 18 Jul 2022
- Ownership
- By LLC
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported in this Form 4 represent shares of common stock of Clene Inc. required to be sold by Mr. Etherington to satisfy tax obligations in connection with the vesting of 80,076 restricted stock awards. The sales occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan at a weighted average price of $4.72; the shares were sold in multiple transactions at prices ranging from $4.36 to $4.94, inclusive.
Footnote F2
The securities are owned by RDE RX Ventures LLC. Mr. Etherington is the manager of RDE RX Ventures LLC. The shares owned by RDE RX Ventures LLC may also be deemed to be beneficially owned by Mr. Etherington.